Skip to main content
NCBI home page
Cancer Science logoLink to Cancer Science
. 2005 Aug 19;95(10):840–844. doi: 10.1111/j.1349-7006.2004.tb02191.x

Sensitization of human glioblastomas to tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) by NF‐κB inhibitors

Chinatsu Kasuga 1, Tomohiko Ebata 2,✉, Nobuhiko Kayagaki 2, Hideo Yagita 2, Makoto Hishii 1, Hajime Aral 1, Kiyoshi Sato 1, Ko Okumura 2
PMCID: PMC11160086  PMID: 15504253

Abstract

Glioblastoma is the most malignant form of primary brain tumor in adults, with no effective therapy and a low survival rate. TRAIL is a member of the TNF family, which selectively induces apoptosis in certain neoplastic cells, but not normal cells. In this study, we investigated the sensitivity of 7 human glioblastoma cell lines to TRAIL and the expression in them of TRAIL receptors. TRAIL exhibited significant cytotoxicity in 5 of 7 glioma cell lines. These glioblastoma cell lines expressed TRAIL‐R2, but not TRAIL‐R1, R3, or R4. However, no correlation was observed between the TRAIL sensitivity and the TRAIL‐R2 expression level, suggesting that there is an additional determinant of TRAIL sensitivity. Treatments with NF‐κB inhibitors, such as LLnL, MG132, and SN50, significantly increased the sensitivity of glioma cells to TRAIL. These results suggested that activation of NF‐κB is a protective mechanism against TRAIL‐induced cell death in some glioma cells, and thus NF‐κB inhibitors may be useful to improve the clinical treatment of glioblastoma with TRAIL.

Abbreviations:

TNF

tumor necrosis factor

NF‐κB

nuclear factor κB

1κB

inhibitory NF‐κB

IKK

IκB kinase

FILP

FLICE inhibitory protein

IAP

inhibitor of apoptosis

References

  • 1. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673–82. [DOI] [PubMed] [Google Scholar]
  • 2. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo‐2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 1996; 271: 12687–90. [DOI] [PubMed] [Google Scholar]
  • 3. Schneider P, Thome M, Burns K, Bodmer JL, Hofmann K, Kataoka T, Holler N, Tschopp J. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD‐dependent apoptosis and activate NF‐kappaB. Immunity 1997; 7: 831–6. [DOI] [PubMed] [Google Scholar]
  • 4. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276: 111–3. [DOI] [PubMed] [Google Scholar]
  • 5. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain‐containing receptor for TRAIL. Science 1997; 277: 815–8. [DOI] [PubMed] [Google Scholar]
  • 6. Walczak H, Degli‐Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA, Goodwin RG, Rauch CT. TRAIL‐R2: a novel apoptosis‐mediating receptor for TRAIL. EMBO J 1997; 16: 5386–97. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Screaton GR, Mongkolsapaya J, Xu XN, Cowper AE, McMichael AJ, Bell JI. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr Biol 1997; 7: 693–6. [DOI] [PubMed] [Google Scholar]
  • 8. Degli‐Esposti MA, Smolak PJ, Walczak H, Waugh J, Huang CP, DuBose RF, Goodwin RG, Smith CA. Cloning and characterization of TRAIL‐R3, a novel member of the emerging TRAIL receptor family. J Exp Med 1997; 186: 1165–70. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A. Control of TRAIL‐induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277: 818–21. [DOI] [PubMed] [Google Scholar]
  • 10. Schneider P, Bodmer JL, Thome M, Hofmann K, Holler N, Tschopp J. Characterization of two receptors for TRAIL. FEBS Lett 1997; 416: 329–34. [DOI] [PubMed] [Google Scholar]
  • 11. Pan G, Ni J, Yu G, Wei YF, Dixit VM. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling. FEBS Lett 1998; 424: 41–5. [DOI] [PubMed] [Google Scholar]
  • 12. Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D, Yuan J, Gurney A, Goddard AD, Godowski P, Ashkenazi A. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 1997; 7: 1003–6. [DOI] [PubMed] [Google Scholar]
  • 13. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 1998; 273: 14363–7. [DOI] [PubMed] [Google Scholar]
  • 14. Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD‐dependent apoptosis and activate the NF‐kappaB pathway. Immunity 1997; 7: 821–30. [DOI] [PubMed] [Google Scholar]
  • 15. Degli‐Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. The novel receptor TRAIL‐R4 induces NF‐kappaB and protects against TRAIL‐mediated apoptosis, yet retains an incomplete death domain. Immunity 1997; 7: 813–20. [DOI] [PubMed] [Google Scholar]
  • 16. Wu M, Das A, Tan Y, Zhu C, Cui T, Wong MC. Induction of apoptosis in glioma cell lines by TRAIL/Apo‐21. J Neurosci Res 2000; 61: 464–70. [DOI] [PubMed] [Google Scholar]
  • 17. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR, Strom SC. Apoptosis induced in normal human hepatocytes by tumor necrosis factor‐related apoptosis‐inducing ligand. Nat Med 2000; 6: 564–7. [DOI] [PubMed] [Google Scholar]
  • 18. Nakamura M, Rieger J, Weller M, Kim J, Kleihues P, Ohgaki H. APO2L/ TRAIL expression in human brain tumors. Acta Neuropathol (Berl) 2000; 99: 1–6. [DOI] [PubMed] [Google Scholar]
  • 19. Nitsch R, Bechmann I, Deisz RA, Haas D, Lehmann TN, Wendling U, Zipp F. Human brain‐cell death induced by tumour‐necrosis‐factor‐related apoptosis‐inducing ligand (TRAIL). Lancet 2000; 356: 827–8. [DOI] [PubMed] [Google Scholar]
  • 20. Frank S, Kohler U, Schackert G, Schackert HK. Expression of TRAIL and its receptors in human brain tumors. Biochem Biophys Res Commun 1999; 257: 454–9. [DOI] [PubMed] [Google Scholar]
  • 21. Rieger J, Ohgaki H, Kleihues P, Weller M. Human astrocytic brain tumors express AP02L/TRAIL. Acta Neuropathol (Berl) 1999; 97: 1–4. [DOI] [PubMed] [Google Scholar]
  • 22. Rieger J, Naumann U, Glaser T, Ashkenazi A, Weller M. APO2 ligand: a novel lethal weapon against malignant glioma? FEBS Lett 1998; 427: 124–8. [DOI] [PubMed] [Google Scholar]
  • 23. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH. Tumoricidal activity of tumor necrosis factor‐related apoptosis‐inducing ligand in vivo . Nat Med 1999; 5: 157–63. [DOI] [PubMed] [Google Scholar]
  • 24. Pollack IF, Erff M, Ashkenazi A. Direct stimulation of apoptotic signaling by soluble Apo21/tumor necrosis factor‐related apoptosis‐inducing ligand leads to selective killing of glioma cells. Clin Cancer Res 2001; 7: 1362–9. [PubMed] [Google Scholar]
  • 25. Schulze‐Osthoff K, Ferrari D, Los M, Wesselborg S, Peter ME. Apoptosis signaling by death receptors. Eur J Biochem. 1998; 254: 439–59. [DOI] [PubMed] [Google Scholar]
  • 26. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155–62. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Oyaizu N, Kayagaki N, Yagita H, Pahwa S, Ikawa Y. Requirement of cell‐cell contact in the induction of Jurkat T cell apoptosis: the membrane‐anchored but not soluble form of FasL can trigger anti‐CD3‐induced apoptosis in Jurkat T cells. Biochem. Biophys Res Commun 1997; 238: 670–5. [DOI] [PubMed] [Google Scholar]
  • 28. Uno K, Inukai T, Kayagaki N, Goi K, Sato H, Nemoto A, Takahashi K, Kagami K, Yamaguchi N, Yagita H, Okumura K, Koyama‐Okazaki T, Suzuki T, Sugita K, Nakazawa S. TNF‐related apoptosis‐inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome‐positive leukemia cells. Blood 2003; 101: 3658–67. [DOI] [PubMed] [Google Scholar]
  • 29. Palombella VJ, Conner EM, Fuseler JW, Destree A, Davis JM, Laroux FS, Wolf RE, Huang J, Brand S, Elliott PJ, Lazarus D, McCormack T, Parent L, Stein R, Adams J, Grisham MB. Role of the proteasome and NF‐kappaB in streptococcal cell wall‐induced polyarthritis. Proc Natl Acad Sci USA 1998; 95: 15671–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Matsui K, Omura S, Cui H, Schauer SL, Sonenshein GE, Ju ST. Proteasome regulation of Fas ligand cytotoxicity. Eur J Immunol 1997; 27: 2269–78. [DOI] [PubMed] [Google Scholar]
  • 31. Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J. Inhibition of nuclear translocation of transcription factor NF‐kappaB by a synthetic peptide containing a cell membrane‐permeable motif and nuclear localization sequence. J Biol Chem. 1995; 270: 14255–8. [DOI] [PubMed] [Google Scholar]
  • 32. Ghosh S, May MJ, Kopp EB. NF‐kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998; 16: 225–60. [DOI] [PubMed] [Google Scholar]
  • 33. Micheau O, Lens S, Gaide O, Alevizopoulos K, Tschopp J. NF‐kappaB signals induce the expression of c‐FLIP. Mol Cell Biol 2001; 21: 5299–305. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES